Evidence map›Paper›PMID 24427357›Full record

ArticleInternational journal of clinical and experimental pathology2014

Are synchronous and metachronous bilateral breast cancers different? An immunohistochemical analysis aimed at intrinsic tumor phenotype.

Elżbieta Senkus, Jolanta Szade, Beata Pieczyńska, Anna Zaczek, Joanna Pikiel, Katarzyna Sosińska-Mielcarek, Agnieszka Karpińska, Jacek Jassem

Open access · greenAbstract read
PubMed Full text at PMC
In one paragraph

Article in International journal of clinical and experimental pathology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.8field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 16 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Genomic imbalances andMolecular and clinical oncology · 2017
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Elżbieta SenkusDepartment of Oncology and Radiotherapy, Medical University of Gdańsk Gdańsk, Poland.
Jolanta SzadeDepartment of Pathomorphology, Medical University of Gdańsk Gdańsk, Poland.
Beata PieczyńskaDepartment of Pathomorphology, Medical University of Gdańsk Gdańsk, Poland.
Anna ZaczekLaboratory of Cell Biology, Department of Medical Biotechnology, Intercollegiate Faculty of Biotechnology, University of Gdańsk and Medical University of Gdańsk Gdańsk, Poland.
Joanna PikielRegional Oncology Center Gdańsk, Poland.
Katarzyna Sosińska-MielcarekRegional Oncology Center Gdańsk, Poland.
Agnieszka KarpińskaWest-Pomeranian Oncology Center Szczecin, Poland.
Jacek JassemDepartment of Oncology and Radiotherapy, Medical University of Gdańsk Gdańsk, Poland.
Gdańsk Medical University · PLZRE Gdańsk (Poland) · PLWest Pomeranian University of Technology · PL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

unlabelledThe biology and pathomechanism of bilateral breast cancers is not fully understood. We compared the morphological and immunohistochemical characteristics of primary tumors in patients with synchronous bilateral breast cancers and metachronous bilateral breast cancers, with special focus on intrinsic tumor phenotype.

methodsTumor morphology and expression of 8 immunohistochemical markers were assessed in tissue microarrays containing primary breast tumor cores from 113 metachronous bilateral breast cancers and 61 synchronous bilateral breast cancers. Analyzed markers included hormone receptors (estrogen receptor, progesterone receptor), HER2, Ki67, cytokeratin 5/6, E-cadherin, vimentin and epidermal growth factor receptor. Cutoff levels are provided in the table.

resultsMetachronous bilateral breast cancers tumors had lower estrogen receptor expression (p=0.047) and higher expression of cytokeratin 5/6 (p=0.017) and of vimentin (p=0.008); in multivariate analysis only vimentin retained the significance (p=0.01). Ten (13%) and 11 (26%) of metachronous bilateral breast cancers and synchronous bilateral breast cancers had luminal A phenotype, 39 (50%) and 15 (36%) were luminal B HER2-negative, 13 (17%) and 12 (28%) - luminal B HER2-positive, 3 (4%) and 2 (5%) - HER2-positive (not luminal), and 12 (16%) and 2 (5%) had triple negative phenotype (p=0.07).

conclusionMetachronous bilateral breast cancers, compared to synchronous bilateral breast cancers, are characterized by more aggressive phenotype, expressed by lower expression of estrogen receptor and stronger expression of cytokeratin 5/6 and vimentin; this does not, however, translate into differences in the distribution of intrinsic tumor phenotypes.

Indexed as

Biomarkers, TumorBreast NeoplasmsFemaleFunctional LateralityHumansImmunohistochemistryNeoplasms, Multiple PrimaryNeoplasms, Second PrimaryPhenotypeTissue Array AnalysisBiomarkers, TumorBilateral breast cancerimmunohistochemistryintrinsic phenotypemetachronoussynchronous

Identifiers

PMID24427357
PMCPMC3885491
OpenAlexW111424356

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.